The heterogeneity of changes in incidence and survival among lymphoid malignancies in a 30-year French population-based registry

References

• Jaffe ES, Harris NL, Stein H, et al. Pathology and genetics of tumours of haematopoietic and lymphoid tissues. Lyon: IARC; 2001.
   Google Scholar
• Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, et al. Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in2012. Eur J Cancer 2013;49:1374–1403.
   Google Scholar
• Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013;63:11–30.
   PubMed Web of Science ®Google Scholar
• Bosetti C, Levi F, Ferlay J, et al. Incidence and mortality from non-Hodgkin lymphoma in Europe: the end of an epidemic? Int J Cancer 2008;123:1917–1923.
   PubMed Web of Science ®Google Scholar
• Morton LM, Wang SS, Devesa SS, et al. Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood 2006;107:265–276.
   PubMed Web of Science ®Google Scholar
• McLaughlin P, Grillo-Lopez AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998;16:2825–2833.
   PubMed Web of Science ®Google Scholar
• Czuczman MS, Grillo-Lopez AJ, White CA, et al. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol 1999;17:268–276.
   PubMed Web of Science ®Google Scholar
• Coiffier B, Haioun C, Ketterer N, et al. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Blood 1998;92:1927–1932.
   PubMed Web of Science ®Google Scholar
• Morton LM, Turner JJ, Cerhan JR, et al. Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph). Blood 2007;110:695–708.
   PubMed Web of Science ®Google Scholar
• Ahmad OB, Boschi-Pinto C, Lopez AD, et al. Age standardization of rates: a new WHO standard GPE discussion paper series: no. 31. Geneva: World Health Organization; 2001.
   Google Scholar
• Schemper M, Smith TL. A note on quantifying follow-up in studies of failure time. Control Clin Trials 1996;17:343–346.
   PubMedGoogle Scholar
• Perme MP, Stare J, Estève J. On estimation in relative survival. Biometrics 2012;68:113–120.
   PubMed Web of Science ®Google Scholar
• R Core Team. R: A language and environment for statistical computing. Vienna, Austria: R Core Team; 2013.
   Google Scholar
• Therneau TM. A package for survival analysis in S. 2014. R package version 2.37-7. Available from: http://CRAN.R-project.org/package = survival
   Google Scholar
• Perme MP. relsurv: Relative survival. 2013. R package version 2.0-4. Available from: http://CRAN.R-project.org/package = relsurv
   Google Scholar
• Swerdlow SH, Campo E, Harris NL, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC; 2008.
   Google Scholar
• Sant M, Allemani C, Tereanu C, et al. Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project. Blood 2010;116:3724–3734.
   PubMed Web of Science ®Google Scholar
• Chihara D, Ito H, Matsuda T, et al. Differences in incidence and trends of haematological malignancies in Japan and the United States. Br J Haematol 2014;164:536–545.
   PubMed Web of Science ®Google Scholar
• Van de Schans SAM, Gondos A, van Spronsen DJ, et al. Improving relative survival, but large remaining differences in survival for non-Hodgkin's lymphoma across Europe and the United States from 1990 to 2004. J Clin Oncol 2011;29:192–199.
   PubMed Web of Science ®Google Scholar
• Marcos-Gragera R, Allemani C, Tereanu C, et al. Survival of European patients diagnosed with lymphoid neoplasms in 2000-2002: results of the HAEMACARE project. Haematologica 2011;96:720–728.
   PubMed Web of Science ®Google Scholar
• Smith A, Howell D, Patmore R, et al. Incidence of haematological malignancy by sub-type: a report from the Haematological Malignancy Research Network. Br J Cancer 2011;105:1684–1692.
   PubMed Web of Science ®Google Scholar
• Al-Tourah AJ, Gill KK, Chhanabhai M, et al. Population-based analysis of incidence and outcome of transformed non-Hodgkin's lymphoma. J Clin Oncol 2008;26:5165–5169.
   PubMed Web of Science ®Google Scholar
• Monnereau A, Remontet L, Maynadié M, et al. Estimation nationale de l'incidence des cancers en France entre 1980 et 2012. Partie 2 – Hémopathies malignes. Saint-Maurice: Institut de veille sanitaire; 2013.
   Google Scholar
• Danieli C, Remontet L, Bossard N, et al. Estimating net survival: the importance of allowing for informative censoring. Stat Med 2012;31:775–786.
   PubMed Web of Science ®Google Scholar
• Roche L, Danieli C, Belot A, et al. Cancer net survival on registry data: use of the new unbiased Pohar-Perme estimator and magnitude of the bias with the classical methods. Int J Cancer 2013;132:2359–2369.
   PubMed Web of Science ®Google Scholar
• Monnereau A, Troussard X, Belot A, et al. Unbiased estimates of long-term net survival of hematological malignancy patients detailed by major subtypes in France. Int J Cancer 2013;132:2378–2387.
   PubMed Web of Science ®Google Scholar
• Han X, Kilfoy B, Zheng T, et al. Lymphoma survival patterns by WHO subtype in the United States, 1973-2003. Cancer Causes Control 2008;19:841–858.
   PubMed Web of Science ®Google Scholar
• Facon T, Mary JY, Hulin C, et al. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial. Lancet 2007;370:1209–1218.
   PubMed Web of Science ®Google Scholar
• Palumbo A, Bringhen S, Rossi D, et al. A prospective, randomized, phase III study of bortezomib, melphalan, prednisone and thalidomide (VMPT) versus bortezomib, melphalan and prednisone (VMP) in elderly newly diagnosed myeloma patients. Blood 2008;112(Suppl. 1): Abstract 652.
   PubMed Web of Science ®Google Scholar
• Corazziari I, Quinn M, Capocaccia R. Standard cancer patient population for age standardising survival ratios. Eur J Cancer 2004;40:2307–2316.
   PubMed Web of Science ®Google Scholar